The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of
cancers, making it an ideal target for immunotherapeutic strategies. This review highlights …

For more than a decade, tumor immunologists have focused their efforts on discovering
tumor-associated antigens, as a first step toward the design of an effective cancer vaccine …

Currently, there is renewed interest in attempting to recruit the host immune system to
eliminate cancers, and within this renewed activity, MUC1 continues to arouse interest …

MUC1 is a highly glycosylated transmembrane mucin on the luminal surface of epithelial
cells, protecting them from extreme factors. In cancer cells, MUC1 expression is upregulated …

Introduction: Success of HBV vaccines in reducing the incidence of liver cancer, and HPV
vaccines in reducing preneoplastic cervical lesions, demonstrate the potential of cancer …

Mucin1 is a highly glycosylated type 1 transmembrane mucin that ranks second among 75
tumor-related antigens published by the National Cancer Institute, and has been identified …

MUC1 is a potential target in breast cancer immunotherapy as MUC1 is overexpressed in
breast cancer, and is absent or expressed in low level in normal mammary gland. In …

Summation The MUC1 and MUC4 membrane mucins are each composed of a large alpha
(α) and a small beta (β) subunit. The α subunits are fully exposed at the cell surface and …

Mucins represent a family of glycoproteins characterized by repeat domains and a dense O-
glycosylation. During the last two decades, the gene and peptide structures of various …

MUC1 is a membrane-tethered mucin expressed on the ductal cell surface of glandular
epithelial cells. Loss of polarization, overexpression and aberrant glycosylation of MUC1 in …